TMS & Neuromodulation · Part 7

Overview

Major depressive disorder remains the most established clinical use of transcranial magnetic stimulation (TMS), but it is not the only U.S. indication. As of July 10, 2026, specific devices and complete protocols have FDA authorization for adjunctive treatment of adult obsessive-compulsive disorder (OCD), aid in short-term smoking cessation, reduction of anxiety symptoms that accompany major depression, acute and preventive treatment of migraine with a portable single-pulse device, and adjunctive treatment of adult post-traumatic stress disorder (PTSD).¹²³⁴⁵

The word specific is essential. These indications use different coils, targets, pulse patterns, schedules, patient preparations, and sometimes entirely different types of equipment. A clinic that can deliver standard depression rTMS is not automatically equipped or authorized to provide each of these treatments.

The most important points are:

• OCD treatment is an adjunctive, device-specific protocol. It uses a different H-coil and medial-prefrontal target from standard left-prefrontal depression treatment, with symptom provocation as part of the studied workflow.¹⁶
• Smoking-cessation TMS is an aid, not a stand-alone guarantee. A pivotal 262-participant trial supported a specific H-coil protocol paired with smoking-related cue exposure.²⁷
• “Anxious depression” is not a blanket anxiety-disorder indication. The label concerns anxiety symptoms in adults who have major depressive disorder.³
• Migraine uses portable single-pulse TMS. It is prescribed for self-administration and is distinct from office-based repetitive TMS.⁴
• Adult PTSD gained a device-specific U.S. indication in June 2026. The MeRT system uses resting EEG/ECG to select an individualized 8-13-Hz frequency and is authorized as an adjunct, not as proof that all TMS protocols treat PTSD.⁵
• FDA authorization does not establish superiority over all alternatives. Treatment choice still depends on diagnosis, prior care, contraindications, access, patient goals, and the strength and limitations of the supporting evidence.

Evidence cutoff: This article reflects publicly available evidence and U.S. regulatory information through July 10, 2026. Device labeling can change. The diagnosis, age, coil, target, dose, schedule, and adjunctive requirements of the exact authorization should be confirmed before treatment.

---

What “FDA-Authorized” Means for a TMS Device

Most TMS systems are marketed through the FDA’s 510(k) clearance pathway. The original adult OCD device category entered through the De Novo pathway. “FDA-authorized” is a practical umbrella term; “FDA-approved” is often used casually but is usually not the technically precise description for these Class II devices.¹

An authorization is not for “TMS in general.” The label may define:

• the condition and age range;
• whether the treatment is primary or adjunctive;
• the treatment coil and anatomical target;
• pulse frequency, intensity, train pattern, and pulses per session;
• course length and session spacing;
• screening, warnings, contraindications, and preparation procedures.

Evidence from one label should not be transplanted to another device simply because both create magnetic pulses.

Obsessive-Compulsive Disorder

In 2018, the FDA authorized a deep-TMS device category for adjunctive treatment of adults with OCD. “Adjunctive” means it is added to a comprehensive OCD plan, not automatically substituted for exposure and response prevention (ERP), medication, or specialist psychiatric care.¹

How the OCD Protocol Differs

The pivotal protocol used an H7 coil to stimulate medial prefrontal and anterior cingulate cortical regions. The FDA description cautions against interpreting “deep TMS” as the ability to focus selectively on a deep nucleus; H-coils expose a broader volume of cortex and connected networks rather than producing a pinpoint deep-brain target.¹

A brief, individualized symptom provocation occurs before treatment. The clinician and patient identify a moderate trigger—such as a contamination cue, feared uncertainty, or intrusive thought—so the relevant circuit is engaged during stimulation. This should be planned carefully, not improvised as overwhelming exposure. ERP remains the best-established psychotherapy for OCD, and TMS should be integrated with appropriate behavioral care.

What the Pivotal Trial Showed

In the multicenter randomized sham-controlled study, response at six weeks—defined as at least a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)—occurred in 38.1% of active-treatment participants and 11.1% of sham participants in the modified intention-to-treat analysis.¹⁶

Those figures demonstrate a meaningful group difference, not universal remission. Formal remission was uncommon in both groups at the six-week point. Because OCD trials often define response with a 30% Y-BOCS reduction, their percentages should not be compared directly with depression trials that commonly use a 50% threshold.

Patient takeaway: OCD TMS is a reasonable add-on for selected adults whose symptoms remain impairing despite standard care, but it is not a replacement for an accurate OCD diagnosis, adequate ERP, and medication review.

Smoking Cessation

In 2020, the FDA cleared a specific BrainsWay deep-TMS system as an aid in short-term smoking cessation for adults. The protocol uses an H4 coil and smoking-related cue exposure before stimulation, engaging prefrontal and addiction-related circuitry.²

What the Evidence Showed

The pivotal multicenter double-blind trial enrolled 262 chronic smokers. In the FDA analysis, the four-week continuous quit rate was 17.1% with active treatment and 7.9% with sham in the intention-to-treat safety population. Among participants with at least four weeks of diary records, rates were 27.3% and 11.3%, respectively.² The peer-reviewed report also found lower cigarette consumption and craving with active treatment.⁷

The trial supports a genuine short-term aid, while the absolute quit rate shows why TMS should not be marketed as a stand-alone cure for nicotine dependence. A complete plan may include:

• a defined quit date and counseling;
• nicotine replacement, varenicline, bupropion, or another evidence-based medication when medically appropriate;
• management of withdrawal, mood symptoms, and triggers;
• long-term relapse-prevention follow-up.

Coverage and availability are more limited than for depression TMS.

Anxiety Symptoms That Accompany Major Depression

Several TMS systems have labeling that includes decreasing anxiety symptoms in adults with major depressive disorder who may have comorbid anxiety symptoms.³ This is sometimes shortened in marketing to “FDA-cleared for anxiety,” which can be misleading.

The label does not establish a general indication for:

• generalized anxiety disorder without major depression;
• panic disorder;
• social anxiety disorder;
• specific phobia;
• health anxiety or other primary anxiety syndromes.

When anxiety is part of a major depressive episode, it may improve alongside depression with an authorized left-prefrontal protocol. Primary anxiety disorders require their own diagnosis and evidence-based treatment plan, and TMS use may be investigational or off-label.

Migraine: A Different Form of TMS

The SAVI Dual Migraine Therapy is a portable prescription single-pulse TMS (sTMS) device. It is FDA-cleared for acute and prophylactic treatment of migraine in adolescents age 12 and older and adults. Patients self-administer pulses with the device positioned at the back of the head according to the prescription and instructions.⁴

This differs from office-based depression TMS in nearly every practical way:

• single or separated pulses rather than thousands of repetitive pulses;
• home or office self-administration rather than a multiweek clinic course;
• an occipital placement and migraine-specific dosing schedule;
• a distinct device classification and safety label.

Earlier randomized trials supported acute treatment of migraine with aura, and later studies contributed to preventive use and broader labeling.⁸⁹ sTMS can be useful for some patients who prefer a non-drug option or need to reduce medication exposure, but response is not universal and migraine diagnosis still matters.

Post-Traumatic Stress Disorder: The June 2026 MeRT Clearance

On June 3, 2026, the FDA cleared the MeRT system as an adjunct for treatment of adults with PTSD. It combines a resting, eyes-closed EEG/ECG analysis algorithm with a compatible MagVenture TMS system. The algorithm recommends an individualized stimulation frequency between 8 and 13 Hz; treatment is delivered over the dorsomedial prefrontal cortex for 20-25 sessions, generally one session per day over four to five weeks.⁵

What the Pivotal Trial Showed

The multisite double-blind randomized sham-controlled trial included 158 adults—77 assigned to active treatment and 81 to sham—with 84% completing treatment. Active treatment produced statistically greater improvement on both the patient-reported PCL-5 and clinician-administered CAPS-5 PTSD measures. The FDA summary reported standardized treatment effects of approximately 0.32 on PCL-5 and 0.51 on CAPS-5.⁵

Two limitations are especially important:

1. The clearance applies to the complete MeRT system and protocol. It does not establish that conventional depression TMS, another EEG-personalized method, or any arbitrary PTSD target is equivalent.
2. The trial did not isolate the algorithm’s independent contribution. The FDA summary explicitly states that the study was designed to test the MeRT system as a whole, not to determine whether EEG-derived frequency selection works better than a fixed frequency.⁵

PTSD treatment should remain trauma-informed and integrated with evidence-based psychotherapy and medication when appropriate. “Adjunct” is not a minor word: TMS should not displace urgent safety planning, treatment of substance use, or established trauma-focused care.

Different Indications Require Different Treatment Systems

What Is Not Established by These Clearances?

The existence of authorized protocols does not establish that:

• all coils or machines can deliver them;
• a similar-looking off-label protocol has the same benefit;
• one authorized TMS treatment is superior to medication, psychotherapy, or another device;
• insurance will cover the treatment;
• every patient with the diagnosis is an appropriate candidate;
• benefit will last indefinitely without follow-up or additional care.

Questions to Ask About a Non-Depression TMS Treatment

• What exact FDA submission or label supports this use?
• Is the indication for my age and diagnosis?
• Is treatment adjunctive, and what standard care should continue?
• Which coil, target, intensity, frequency, and schedule are required?
• Does the clinic own the authorized equipment and use the studied workflow?
• What were the absolute active and sham outcomes in the pivotal trial?
• How will my symptoms, function, adverse effects, and durability be measured?
• What are the alternatives, costs, and insurance limitations?

Bottom line: TMS now has several established U.S. uses beyond adult depression, but each is a separate medical treatment—not a generic feature of every TMS machine. OCD, smoking cessation, comorbid anxiety symptoms in MDD, migraine, and the new adult PTSD indication differ in device, coil, target, dosing, and supporting evidence. The safest interpretation is protocol-specific: verify the exact label, preserve established standard care, and judge benefit by transparent outcomes rather than by the word “TMS” alone.

Previous: What to Expect During a Course of TMS Treatment
Next: The TMS Frontier: Emerging and Investigational Directions

---

References

1. U.S. Food and Drug Administration. De Novo Classification Request: BrainsWay Deep TMS System for adult obsessive-compulsive disorder (DEN170078). Decision August 17, 2018.
2. U.S. Food and Drug Administration. BrainsWay Deep TMS System as an aid in short-term smoking cessation for adults: 510(k) Summary (K200957). August 24, 2020.
3. U.S. Food and Drug Administration. NeuroStar labeling for decreasing anxiety symptoms in adults with major depressive disorder and comorbid anxiety symptoms: K222230. August 24, 2022.
4. U.S. Food and Drug Administration. SAVI Dual Migraine Therapy: acute and prophylactic single-pulse TMS for migraine in adolescents age 12 and older and adults (K230358). May 16, 2023.
5. U.S. Food and Drug Administration. MeRT System for adjunctive treatment of adult PTSD: 510(k) Summary (K260402). June 3, 2026.
6. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry. 2019;176(11):931-938. doi:10.1176/appi.ajp.2019.18101180.
7. Zangen A, Moshe H, Martinez D, et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021;20(3):397-404. doi:10.1002/wps.20905.
8. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomized, double-blind, sham-controlled trial. Lancet Neurol. 2010;9(4):373-380.
9. Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single-arm, open-label observational study of sTMS for migraine prevention. Cephalalgia. 2018;38(6):1038-1048.

Medical disclaimer. This article is provided for general educational and informational purposes only. It does not constitute individualized medical advice, diagnosis, treatment, a recommendation for any specific test or therapy, or informed consent. Medical information changes over time, and this article may not reflect developments occurring after its stated review date or apply to your individual circumstances. Do not disregard or delay professional medical advice, or start, stop, or change any medication or treatment, based on this article. Discuss personal medical decisions with a qualified healthcare professional who can evaluate your individual history and circumstances. Accessing or using this website does not, by itself, create a physician–patient relationship with Los Altos Neurology or any of its clinicians. Do not use this website for urgent or emergency medical concerns; call 911 or seek immediate emergency care. Although Los Altos Neurology makes reasonable efforts to provide accurate and current information, it does not guarantee that all content is complete, current, or applicable to every individual. See our full Medical Disclaimer.